Skip to content
OpenCapital
Get started

Trevi Therapeutics, Inc. TRVI Finance Lease, Principal Payments

Finance Lease, Principal Payments at other companies

LQD
Liquidia CorporationLQDA
——

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K—
Free cash flow-$16.8M—

Valuation

See full
Market cap$2.47B+152%
Enterprise value$2.45B+157%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0×0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s finance lease, principal payments.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trevi Therapeutics, Inc.'s finance lease, principal payments?
Trevi Therapeutics, Inc. (TRVI) reported finance lease, principal payments of $0 in Q4 2025.
How has Trevi Therapeutics, Inc.'s finance lease, principal payments changed year-over-year?
Trevi Therapeutics, Inc.'s finance lease, principal payments decreased by 100.0% year-over-year, from $31K to $0.
What is the long-term trend for Trevi Therapeutics, Inc.'s finance lease, principal payments?
Over 2 years (2023 to 2025), Trevi Therapeutics, Inc.'s finance lease, principal payments has grown at a -66.1% compound annual growth rate (CAGR), from $96K to $11K.